DAPH-7

PKC inhibitor



BML-EI387-0001	1 mg	42.00 USD

DAPH-7 induces remodeling of Sup35 prion-specific intermolecular interfaces to create morphologically altered aggregates with diminished infectivity and self-templating activity. Inhibits Sup35 NM domain fibrillization with an IC₅₀=3.4µM. DAPH-7 remodels β-amyloid (1-42) fibers and inhibits their de novo assembly. Selective PKCβII inhibitor. IC₅₀ is 410nM for PKCβII vs 3.8µM for PKCβI.

Product Specification

Alternative Name:	4,5-bis[(4-Fluorophenyl)amino]phthalimide, CGP 53353

Formula:	C₂₀H₁₃F₂N₃O₂

MW:	365.3

Purity:	≥98% (TLC)

Appearance:	Orange solid.

CAS:	145915-60-2

Solubility:	Soluble in DMSO (>25mg/ml) or ethanol (5mg/ml).

Long Term Storage:	-20°C

Background / Technical Information:	Please click here for the comprehensive product data sheet.